Cargando…
Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model
BACKGROUND: Folate-nanoliposomes delivery system has emerged recently as a specific and safety delivery method and gradually used as the carrier of a variety kinds of drugs including compounds, plasmids and siRNAs. METHODS: In this study, we established a bone marrow and bone metastasis xenograft mo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702425/ https://www.ncbi.nlm.nih.gov/pubmed/23806172 http://dx.doi.org/10.1186/1475-2867-13-65 |
_version_ | 1782275804108947456 |
---|---|
author | Zhu, Qiqi Feng, Chen Liao, Weiwei Zhang, Yan Tang, Suoqin |
author_facet | Zhu, Qiqi Feng, Chen Liao, Weiwei Zhang, Yan Tang, Suoqin |
author_sort | Zhu, Qiqi |
collection | PubMed |
description | BACKGROUND: Folate-nanoliposomes delivery system has emerged recently as a specific and safety delivery method and gradually used as the carrier of a variety kinds of drugs including compounds, plasmids and siRNAs. METHODS: In this study, we established a bone marrow and bone metastasis xenograft mouse model by injecting the LA-N-5 cell into the bone marrow cavity. Fluorescence microscopy, TUNEL Assay, Quantitative RT-PCR and western blot were conducted to analysis the distribution of folate-nanoliposomes entrapped MYCN (V-myc myelocytomatosis viral related oncogene) siRNA in mice and the relevant suppression effect. RESULTS: The folate-nanoliposomes entrapped MYCN siRNA can be specifically distributed in tumor tissues. Further study shows that folate-nanoliposomes entrapped MYCN siRNA lead to MYCN mRNA expression significantly down-regulated (>50%, and p < 0.05) compared with negative control siRNA treatment. MYCN protein expression was inhibited about 60% in vivo, thus induced tumor cell apoptosis markedly. CONCLUSION: This study point to a new way for treatment of metastatic neuroblastoma and could widen the application of folate-nanoliposomes delivery system in tumor therapy. |
format | Online Article Text |
id | pubmed-3702425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37024252013-07-06 Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model Zhu, Qiqi Feng, Chen Liao, Weiwei Zhang, Yan Tang, Suoqin Cancer Cell Int Primary Research BACKGROUND: Folate-nanoliposomes delivery system has emerged recently as a specific and safety delivery method and gradually used as the carrier of a variety kinds of drugs including compounds, plasmids and siRNAs. METHODS: In this study, we established a bone marrow and bone metastasis xenograft mouse model by injecting the LA-N-5 cell into the bone marrow cavity. Fluorescence microscopy, TUNEL Assay, Quantitative RT-PCR and western blot were conducted to analysis the distribution of folate-nanoliposomes entrapped MYCN (V-myc myelocytomatosis viral related oncogene) siRNA in mice and the relevant suppression effect. RESULTS: The folate-nanoliposomes entrapped MYCN siRNA can be specifically distributed in tumor tissues. Further study shows that folate-nanoliposomes entrapped MYCN siRNA lead to MYCN mRNA expression significantly down-regulated (>50%, and p < 0.05) compared with negative control siRNA treatment. MYCN protein expression was inhibited about 60% in vivo, thus induced tumor cell apoptosis markedly. CONCLUSION: This study point to a new way for treatment of metastatic neuroblastoma and could widen the application of folate-nanoliposomes delivery system in tumor therapy. BioMed Central 2013-06-27 /pmc/articles/PMC3702425/ /pubmed/23806172 http://dx.doi.org/10.1186/1475-2867-13-65 Text en Copyright © 2013 Zhu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Primary Research Zhu, Qiqi Feng, Chen Liao, Weiwei Zhang, Yan Tang, Suoqin Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title | Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title_full | Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title_fullStr | Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title_full_unstemmed | Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title_short | Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
title_sort | target delivery of mycn sirna by folate-nanoliposomes delivery system in a metastatic neuroblastoma model |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702425/ https://www.ncbi.nlm.nih.gov/pubmed/23806172 http://dx.doi.org/10.1186/1475-2867-13-65 |
work_keys_str_mv | AT zhuqiqi targetdeliveryofmycnsirnabyfolatenanoliposomesdeliverysysteminametastaticneuroblastomamodel AT fengchen targetdeliveryofmycnsirnabyfolatenanoliposomesdeliverysysteminametastaticneuroblastomamodel AT liaoweiwei targetdeliveryofmycnsirnabyfolatenanoliposomesdeliverysysteminametastaticneuroblastomamodel AT zhangyan targetdeliveryofmycnsirnabyfolatenanoliposomesdeliverysysteminametastaticneuroblastomamodel AT tangsuoqin targetdeliveryofmycnsirnabyfolatenanoliposomesdeliverysysteminametastaticneuroblastomamodel |